Jubilant Pharmova's Cadista Facility Receives VAI Status from USFDA

Jubilant Pharmova Ltd. has informed that its subsidiary, Jubilant Cadista's, facility has cleanly closed an inspection by receiving an Establishment Inspection Report (EIR) from the U.S. Food and Drug Administration (USFDA). The plant has been rated as Voluntary Action Indicated (VAI), meaning that although objectionable conditions were present during inspection, they are not strong enough to trigger regulatory action. This is a positive development for the compliance status of the company and its operations in the U.S. market.

 

Sources: Economic Times, Jubilant Pharmova regulatory filings, March 12, 2025